We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD (BDX) to Expand Base in Pharmacy Automation With New Buyout
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, along with Frazier Healthcare Partners, recently announced a definitive agreement for the former to acquire Parata Systems for $1.525 billion. The transaction is expected to close by the end of the first half of BD's fiscal year 2023, upon the satisfaction of customary closing conditions, including receipt of regulatory clearances.
It is worth mentioning that the transaction is expected to be immediately accretive to BD’s revenue growth, adjusted operating margin and adjusted earnings per share, and improve its ability to achieve its long-range targeted growth.
The latest buyout is anticipated to significantly expand BD’s presence in the global pharmacy automation space and complement its Medication Management Solutions business unit.
Rationale Behind the Buyout
Parata Systems’ portfolio of pharmacy automation solutions aids a growing network of pharmacies to lower costs, boost patient safety and enhance patient experience. On the back of automation and advanced software, pharmacists will be able to dedicate more time to higher-value clinical work and patient interactions to help improve medication adherence, medication safety and patient outcomes.
Following the buyout, BD’s Medication Management Solutions business unit will be complemented with a new set of technologies across the care continuum, including acute care health systems, retail pharmacies, long-term care and home settings.
Per BD’s management, the addition of Parata Systems is expected to aid BD to advance its 2025 growth strategy around smart, connected care and enabling new care settings.
Industry Prospects
Per a report by MarketsandMarkets, the global pharmacy automation market is anticipated to reach $8.2 billion by 2027 from $5.6 billion in 2022 at a CAGR of 7.9%. Factors like growing focus on automation to reduce labor costs and increasing specialty drug dispensing are likely to drive the market.
Given the market potential, the latest buyout is expected to significantly strengthen BD’s business worldwide.
Recent Developments
This month, BD announced its plans to unveil a new cell sorting technology — BD FACSDiscover S8 Cell Sorter — at the recently concluded International Society for Advancement of Cytometry CYTO 2022 conference.
In May, BD announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform, BD COR MX instrument. The instrument, which has received the FDA’s 510(k) clearance, is a new analytic instrument option for the BD COR System.
The same month, BD announced the expansion of its strategic partnership with Babson Diagnostics to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for diagnostic testing.
Price Performance
The BD stock has gained 5.9% over the past year against the industry’s 4.5% fall and the S&P 500's 5.2% decline.
Image Source: Zacks Investment Research
Zacks Rank & Stocks to Consider
Currently, BD carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , HealthEquity, Inc. (HQY - Free Report) and Masimo Corporation (MASI - Free Report) .
AMN Healthcare, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 1.1%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.6%.
AMN Healthcare has gained 7.8% against the industry’s 63.7% fall in the past year.
HealthEquity, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 19.4%. HQY’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average beat being 1.4%.
HealthEquity has lost 16.2% compared with the industry’s 63.7% fall over the past year.
Masimo, carrying a Zacks Rank #2 at present, has an earnings yield of 3.3% against the industry’s negative yield. MASI’s earnings surpassed estimates in the trailing four quarters, the average beat being 4.4%.
Masimo has lost 33.6% compared with the industry’s 16.1% fall over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
BD (BDX) to Expand Base in Pharmacy Automation With New Buyout
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, along with Frazier Healthcare Partners, recently announced a definitive agreement for the former to acquire Parata Systems for $1.525 billion. The transaction is expected to close by the end of the first half of BD's fiscal year 2023, upon the satisfaction of customary closing conditions, including receipt of regulatory clearances.
It is worth mentioning that the transaction is expected to be immediately accretive to BD’s revenue growth, adjusted operating margin and adjusted earnings per share, and improve its ability to achieve its long-range targeted growth.
The latest buyout is anticipated to significantly expand BD’s presence in the global pharmacy automation space and complement its Medication Management Solutions business unit.
Rationale Behind the Buyout
Parata Systems’ portfolio of pharmacy automation solutions aids a growing network of pharmacies to lower costs, boost patient safety and enhance patient experience. On the back of automation and advanced software, pharmacists will be able to dedicate more time to higher-value clinical work and patient interactions to help improve medication adherence, medication safety and patient outcomes.
Following the buyout, BD’s Medication Management Solutions business unit will be complemented with a new set of technologies across the care continuum, including acute care health systems, retail pharmacies, long-term care and home settings.
Per BD’s management, the addition of Parata Systems is expected to aid BD to advance its 2025 growth strategy around smart, connected care and enabling new care settings.
Industry Prospects
Per a report by MarketsandMarkets, the global pharmacy automation market is anticipated to reach $8.2 billion by 2027 from $5.6 billion in 2022 at a CAGR of 7.9%. Factors like growing focus on automation to reduce labor costs and increasing specialty drug dispensing are likely to drive the market.
Given the market potential, the latest buyout is expected to significantly strengthen BD’s business worldwide.
Recent Developments
This month, BD announced its plans to unveil a new cell sorting technology — BD FACSDiscover S8 Cell Sorter — at the recently concluded International Society for Advancement of Cytometry CYTO 2022 conference.
In May, BD announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform, BD COR MX instrument. The instrument, which has received the FDA’s 510(k) clearance, is a new analytic instrument option for the BD COR System.
The same month, BD announced the expansion of its strategic partnership with Babson Diagnostics to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for diagnostic testing.
Price Performance
The BD stock has gained 5.9% over the past year against the industry’s 4.5% fall and the S&P 500's 5.2% decline.
Image Source: Zacks Investment Research
Zacks Rank & Stocks to Consider
Currently, BD carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , HealthEquity, Inc. (HQY - Free Report) and Masimo Corporation (MASI - Free Report) .
AMN Healthcare, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 1.1%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.6%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 7.8% against the industry’s 63.7% fall in the past year.
HealthEquity, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 19.4%. HQY’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average beat being 1.4%.
HealthEquity has lost 16.2% compared with the industry’s 63.7% fall over the past year.
Masimo, carrying a Zacks Rank #2 at present, has an earnings yield of 3.3% against the industry’s negative yield. MASI’s earnings surpassed estimates in the trailing four quarters, the average beat being 4.4%.
Masimo has lost 33.6% compared with the industry’s 16.1% fall over the past year.